8-K: Protagonist Therapeutics Advances Key Drug Candidates

Protagonist Therapeutics, Inc. provides an updated corporate presentation detailing progress on its lead drug candidates, Icotrokinra and Rusfertide, including recent NDA submissions and a robust R&D pipeline.

Summary

• Icotrokinra, an oral IL-23R antagonist, had its NDA filed for plaque psoriasis in July 2025 and MAA submitted in September 2025. Phase 3 studies are ongoing for Psoriatic Arthritis (PsA), Ulcerative Colitis (UC), and Crohn's Disease (CD), demonstrating best-in-class oral efficacy and established safety.
• Rusfertide, a SC weekly hepcidin mimetic, had its NDA submitted for Polycythemia Vera (PV) in December 2025. The Phase 3 VERIFY study met its primary and all four key secondary endpoints, showing durable hematocrit (Hct) control and improved patient-reported outcomes. It holds Orphan Drug, Fast Track, and Breakthrough Therapy designations.
• PN-881, an oral IL-17 antagonist, initiated Phase 1 in Q4 2025, targeting psoriasis, PsA, hidradenitis suppurativa, and spondyloarthritis, showing potent inhibition of IL-17AA, AF, and FF in preclinical studies.
• PN-8047, an oral hepcidin functional mimetic, was nominated as a development candidate in Q4 2025, with IND-enabling studies ongoing and Phase 1 initiation expected by year-end.
• Anti-Obesity programs include PN-477 (triple agonist GLP-1R, GIPR, GCGR) with Phase 1 initiation planned for mid-2026 (SC) and 2H 2026 (oral), and PN-458 (dual GLP-1R, GIPR) nominated as a development candidate in Q4 2025, with Phase 1 initiation expected in Q4 2026.
• Potential development milestones from Johnson & Johnson (Icotrokinra) could reach ~$205 million through 2028, and from Takeda (Rusfertide) up to $1.675 billion under an opted-in scenario, in addition to royalties.
• Total potential sales milestones are up to $425 million for Icotrokinra and $775 million for Rusfertide.

Sentiment

Score: 9

Explanation: The filing presents a highly positive outlook with multiple drug candidates advancing, two major NDA submissions for potential blockbuster drugs with strong clinical data and market potential. The robust pipeline of wholly-owned assets, particularly in the high-growth anti-obesity and immunology sectors, provides substantial future growth drivers. The company's strong cash position and potential for substantial milestone and royalty revenues from partnerships further de-risk its development efforts and enhance its financial outlook.

Positives

• NDA filed for Icotrokinra in plaque psoriasis (July 2025) and MAA submitted (September 2025), positioning it for potential approval and launch in 2H 2026.
• NDA submitted for Rusfertide in Polycythemia Vera (December 2025), with potential for approval and launch in 2H 2026.
• Icotrokinra demonstrated best-in-class oral efficacy and established safety in psoriasis and ulcerative colitis, achieving high rates of skin clearance and durable response, and superiority versus deucravacitinib.
• Rusfertide's Phase 3 VERIFY study met its primary and all four key secondary endpoints, showing durable Hct control and statistically significant improvements in patient-reported outcomes (MFSAF TSS7 and PROMIS Fatigue SF-8a T-Score).
• Rusfertide has received Orphan Drug, Fast Track, and Breakthrough Therapy designations, indicating significant regulatory support and unmet medical need.
• Significant potential development and sales milestones from partnerships: up to $205 million from Johnson & Johnson for Icotrokinra and up to $1.675 billion from Takeda for Rusfertide (opted-in scenario), plus substantial royalties.
• A robust R&D pipeline with multiple wholly-owned programs (PN-881, PN-8047, PN-477, PN-458) advancing to clinical stages, targeting large market opportunities in immunology, hematology, and obesity.
• PN-881 shows similar potency to Bimekizumab and is approximately 70-fold more potent than Secukinumab in preclinical models, suggesting a differentiated profile in the IL-17 antagonist space.
• PN-477 and PN-458 show promising preclinical data for anti-obesity, with potential for both oral and subcutaneous dosing, addressing patient convenience and market demand.
• The company maintains a strong cash position, enabling it to fund internal, fully-owned programs to clinical Proof of Concept and consider capital return to shareholders.

Risks

• Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond control.
• Future results of operations and financial position may differ materially from projections.
• The achievement and timing of milestone and royalty payments from Johnson & Johnson and Takeda are not guaranteed.
• Potential market opportunities for product candidates may not materialize as expected.
• The impact of actions by the U.S. Food and Drug Administration (FDA) and foreign regulatory agencies, including expectations regarding timing of approvals, is uncertain.
• Expectations regarding timing and announcements related to pre-clinical and clinical programs are subject to change.
• The scope of protection for intellectual property rights covering product candidates may not be established or maintained.
• Products under clinical investigation have not yet been approved for marketing by the FDA and are currently limited by Federal law to investigational use, with no representation made as to their safety or effectiveness.

Future Outlook

The company anticipates potential blockbuster approvals for Icotrokinra in plaque psoriasis and Rusfertide in Polycythemia Vera in the second half of 2026. Multiple R&D readouts are expected, including Phase 1 topline results for PN-881 (1H 2026), PN-477sc (2H 2026), PN-477o (1H 2027), and PN-8047 (1H 2027). Phase 2 initiations are planned for PN-881 (Q4 2026) and PN-8047 (2H 2027). The company aims to fund internal, fully-owned programs to clinical Proof of Concept and is considering opportunistic share buybacks and dividends.

Management Comments

• Our targets are biologically and commercially validated.
• We offer strong differentiation versus existing therapies.
• We anticipate two potential blockbuster approvals, multiple R&D readouts, and maintain a strong cash position.

Industry Context

The company is strategically positioned in several high-growth therapeutic areas, developing first-in-class oral therapies (Icotrokinra, PN-881) in markets currently dominated by injectables, thereby addressing a significant unmet need for patient convenience and potentially expanding market access. Its robust anti-obesity pipeline (PN-477, PN-458) targets a massive untapped opportunity, aiming for oral and more effective agents with improved tolerability compared to existing GLP-1R agonists. Rusfertide addresses a critical unmet need for an RBC-specific treatment option in Polycythemia Vera, where current standards of care are often inadequate, potentially transforming the treatment paradigm.

Comparison to Industry Standards

• Icotrokinra demonstrated 'best-in-class oral efficacy' in psoriasis and ulcerative colitis, achieving high rates of skin clearance and durable response, and superiority versus deucravacitinib in ICONIC-ADVANCE studies.
• Cross-trial comparisons in ulcerative colitis show Icotrokinra's clinical response (64%) and remission (30%) rates are higher than or comparable to other oral agents like Rinvoq (JAK Inhibitor, 51% clinical response, 10% remission) and Velsipity (S1PR modulator, 57% clinical response, 16% remission), and IL-23 mAbs such as Skyrizi (46% clinical response, 10% remission) and Tremfya (50% clinical response, 26% remission) at their respective endpoints.
• PN-881 potently inhibits IL-17AA, AF, and FF, showing similar potency to Bimekizumab and approximately 70-fold more potency than Secukinumab (both injectable IL-17 agents) in preclinical models.
• PN-477 (triple agonist) preclinical data shows body weight loss comparable to Retatrutide (Eli Lilly's injectable triple agonist) with subcutaneous dosing, and dose-proportional weight loss of up to 50% with oral dosing in Diet-Induced Obese (DIO) mice. It is designed to provide maximal weight loss and optimal body composition similar to retatrutide and GI tolerability of tirzepatide.
• PN-458 (dual agonist) exhibits higher potency than Tirzepatide (Eli Lilly's dual GLP-1R/GIPR agonist) for GLP-1R and GIPR, with higher GIPR potency potentially favorable for better GI tolerability. Preclinical weight loss benchmarks favorably versus tirzepatide.

Stakeholder Impact

• Shareholders: Potential for significant value creation through anticipated drug approvals, substantial milestone payments, and a robust pipeline. The company is considering opportunistic share buybacks and dividends.
• Patients: Potential for new, effective, and convenient oral treatment options for chronic inflammatory diseases (psoriasis, UC, CD, PsA), polycythemia vera, and obesity, addressing significant unmet medical needs.
• Employees: Continued R&D and potential commercialization efforts suggest stable or growing employment opportunities within the company.
• Partners (Johnson & Johnson, Takeda): Continued collaboration and potential for successful drug development and commercialization, leading to shared financial benefits.

Next Steps

• Icotrokinra: US approval/launch for Psoriasis (2H 2026). Primary completion dates for Ph3 PsA 1 (May 2026), PsA 2 (Feb 2027), UC (Jan 2028), CD (Sept 2028).
• Rusfertide: US approval/launch for PV (2H 2026). Opt-in/Opt-out decision (Q2/Q3 2026).
• PN-881: Phase 1 topline results (1H 2026), Phase 2 Psoriasis initiation (Q4 2026), Phase 2 HS initiation (2H 2027).
• PN-477sc: Phase 1 initiation (Mid 2026), Phase 1 topline results (2H 2026).
• PN-477o: Phase 1 initiation (2H 2026), Phase 1 topline results (1H 2027).
• PN-8047: Phase 1 initiation (Year-end 2026), Topline results from Phase 1 (1H 2027), Phase 2 initiation (2H 2027).
• PN-458sc/o: Phase 1 initiation (Q4 2026).
• Discovery programs: Continue lead optimization and preclinical development for AmylinR-based mono & poly-agonists and Oral IL-4R antagonist.

Key Dates

Recommendation

The filing details significant progress on multiple fronts, including two NDA submissions for potential blockbuster drugs (Icotrokinra and Rusfertide) with strong clinical data and substantial market potential. The robust pipeline of wholly-owned assets, particularly in the high-growth anti-obesity and immunology sectors, provides substantial future growth drivers. The company's strong cash position and potential for significant milestone and royalty revenues from partnerships further de-risk its development efforts and enhance its financial outlook. This combination of near-term catalysts and long-term growth potential makes it a compelling investment.

Keywords

Protagonist Therapeutics, PTGX, Icotrokinra, Rusfertide, Polycythemia Vera, Psoriasis, Ulcerative Colitis, Crohn's Disease, Psoriatic Arthritis, IL-23R antagonist, Hepcidin mimetic, IL-17 antagonist, Anti-obesity, GLP-1R, GIPR, GCGR, Peptide therapeutics, Clinical trials, NDA, MAA, FDA approval, Biotechnology, Pharmaceuticals